NEWS & EVENTS

Category Archives: Company

Organon Completes Acquisition of Forendo Pharma

Organon (NYSE: OGN), a global women’s healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo’s lead candidate, FOR-6219, is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor entering Phase 2 clinical development for endometriosis. Forendo’s pipeline […]

Organon to Acquire Forendo Pharma

Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an […]

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women’s health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated […]

Forendo Pharma Appoints Dr Cristina Csimma as Chair of the Board of Directors

Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women’s health, today announced that Dr Cristina Csimma has been appointed as Chair of the Board of Directors. Cristina brings with her deep expertise in the biopharmaceutical, venture capital, and academic sectors. Commenting on the appointment, Risto Lammintausta, Chief Executive Officer of Forendo […]

Forendo Pharma signs important License and Collaboration Deal with Leading Pharma Company

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated […]

Endometriosis program Phase 1b Proof of Mechanism Study initiated

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism. The novel oral compound, FOR-6219, is a HSD17B1 inhibitor aiming to reduce estrogen production locally in […]

Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo. Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital III. Claus Andersson, General […]

Positive Phase 1a Results of FOR-6219

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has successfully completed Phase 1a study of its lead program FOR-6219, a novel, tissue specific treatment of endometriosis. FOR-6219 was found to be safe and well tolerated, with good pharmacokinetics at the doses tested. Endometriosis is […]

Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital III Partners (Vesalius III). This is in addition to the €12 million Series A financing in 2014 and €5,7 million R&D loans granted by Business […]

Forendo receives clinical trial authorization to initiate phase I study

Forendo Pharma has received clinical trial authorization (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to commence a study for its lead program, FOR-6219. Endometriosis is a chronic condition that affects up to 10% of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available […]